The effect of covalent cross-links between the membrane components of microcapsules on the dissemination of encapsulated malignant cell

被引:13
作者
Dusseault, Julie [1 ]
Langlois, Genevlve [1 ]
Meunier, Marie-Christine [2 ]
Menard, Martin [1 ]
Perreault, Claude [2 ]
Halle, Jean-Pierre [1 ]
机构
[1] Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Montreal, PQ H1T 2M4, Canada
[2] Univ Montreal, Inst Res Immunol & Ctr, Montreal, PQ H3C 3J7, Canada
关键词
stem cells; immortalized cells; malignant transformation; encapsulation; islet transplantation;
D O I
10.1016/j.biomaterials.2007.10.045
中图分类号
R318 [生物医学工程];
学科分类号
0831 [生物医学工程];
摘要
Stem cells and immortalized cells have considerable therapeutic potential but present risks of malignant transformation. Cell microencapsulation allows transplantation without immunosuppression. We have developed a method for microencapsulating living cells within covalently cross-linked membranes that are chemically and mechanically extremely resistant. We provide herein direct evidence that these microcapsules can prevent malignant cell dissemination. When 20,000 or more nonencapsulated EL-4 thymoma cells were implanted intra peritoneally in mice, all recipients died with widespread metastasis within 26.3 +/- 1.0 days. All recipients of 250,000 EL-4 cells microencapsulated in covalently cross-linked membranes were living and disease-free, 150 days post-implantation. Encapsulation in standard microcapsules only slightly delayed the recipient death. Pancreatic islets transplanted using either type of microcapsule presented similar Survival. We conclude that microencapsulation in covalently cross-linked membranes prevents malignant cell dissemination. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:917 / 924
页数:8
相关论文
共 39 条
[1]
Insulin production by human embryonic stem cells [J].
Assady, S ;
Maor, G ;
Amit, M ;
Itskovitz-Eldor, J ;
Skorecki, KL ;
Tzukerman, M .
DIABETES, 2001, 50 (08) :1691-1697
[2]
Gene- and cell-based therapeutics for type I diabetes mellitus [J].
Bottino, R ;
Lemarchand, P ;
Trucco, M ;
Giannoukakis, N .
GENE THERAPY, 2003, 10 (10) :875-889
[3]
Bouckenooghe T, 2004, GENE EXPRESSION, V12, P83
[4]
MTS colorimetric assay in combination with a live-dead assay for testing encapsulated L929 fibroblasts in alginate poly-L-lysine microcapsules in vitro [J].
Bünger, CM ;
Jahnke, A ;
Stange, J ;
de Vos, P ;
Hopt, UT .
ARTIFICIAL ORGANS, 2002, 26 (02) :111-116
[5]
Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes - First two cases [J].
Calafiore, R ;
Basta, G ;
Luca, G ;
Lemmi, A ;
Montanucci, MP ;
Calabrese, G ;
Racanicchi, L ;
Mancuso, F ;
Brunetti, P .
DIABETES CARE, 2006, 29 (01) :137-138
[6]
Encapsulation for somatic gene therapy [J].
Chang, PL .
BIOARTIFICIAL ORGANS II: TECHNOLOGY, MEDICINE, AND MATERIALS, 1999, 875 :146-158
[7]
SEMIPERMEABLE MICROCAPSULES [J].
CHANG, TMS .
SCIENCE, 1964, 146 (364) :524-&
[8]
Ex vivo fibroblast transduction in rabbits results in long-term (>600 days) factor IX expression in a small percentage of animals [J].
Chen, L ;
Nelson, DM ;
Zheng, ZL ;
Morgan, RA .
HUMAN GENE THERAPY, 1998, 9 (16) :2341-2351
[9]
Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells [J].
Cirone, P ;
Bourgeois, JM ;
Shen, F ;
Chang, PL .
HUMAN GENE THERAPY, 2004, 15 (10) :945-959
[10]
Causes of limited survival of microencapsulated pancreatic islet grafts [J].
de Groot, M ;
Schuurs, TA ;
van Schilfgaarde, R .
JOURNAL OF SURGICAL RESEARCH, 2004, 121 (01) :141-150